Letting the model learn its own target: LIFT-MASLD reaches a 0.836 predictive correlation in an external cohort
Prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) usually fix an endpoint first and then improve the predictor. LIFT-MASLD reverses that order: SCORE learns a weighted phenotype from eight hepatic measures that is most predictable from baseline characteristics, with sparse regression selecting the baseline variables. The phenotype reached a predictive correlation of 0.860 in the HALO cohort, above 0.763 for predicting future liver stiffness from all baseline variables, and 0.836 in the NIDDK external cohort without refitting.